Critical Therapeutics Signs Definitive Agreement to Merge with Cornerstone BioPharma

Business Wire,  May 1, 2008  

• E-mail
• Print
• Link

Safe Harbor for Forward-Looking Statements

Statements in this press release regarding the proposed transaction between Critical Therapeutics and Cornerstone; the expected timetable for completing the transaction; future financial and operating results, including targeted product milestones; benefits and synergies of the transaction; future opportunities for the combined company; the strategy, future operations, financial position, future revenues and projected costs; prospects, plans and objectives of management; and any other statements about the Critical Therapeutics or the Cornerstone management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "plans," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the ability to consummate the transaction; the ability to successfully integrate our operations and employees; the ability to realize anticipated synergies and cost savings; the ability to develop and maintain the necessary sales, marketing, distribution and manufacturing capabilities to commercialize our products, including ZYFLO CR; the ability to transition our management teams effectively; patient, physician and third-party payor acceptance of our products, including ZYFLO CR, as safe and effective therapeutic products; our ability to maintain regulatory approvals to market and sell our products, including ZYFLO CR; the ability to successfully enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; Critical Therapeutics' potential inability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; conducting clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; Critical Therapeutics' ability to obtain the substantial additional funding required to conduct our development and commercialization activities; Critical Therapeutics' dependence on its strategic collaboration with MedImmune, Inc.; the ability to obtain, maintain and enforce patent and other intellectual property protection for our products, discoveries and drug candidates; and the other factors described in Critical Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007, as amended, filed with the SEC and other filings that Critical Therapeutics makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.